Gherbi Karolina, May Lauren T, Baker Jillian G, Briddon Stephen J, Hill Stephen J
Cell Signalling Research Group, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom.
Cell Signalling Research Group, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom
FASEB J. 2015 Jul;29(7):2859-71. doi: 10.1096/fj.14-265199. Epub 2015 Apr 2.
At the β1-adrenoceptor, CGP 12177 potently antagonizes agonist responses at the primary high-affinity catecholamine conformation while also exerting agonist effects of its own through a secondary low-affinity conformation. A recent mutagenesis study identified transmembrane region (TM)4 of the β1-adrenoceptor as key for this low-affinity conformation. Others suggested that TM4 has a role in β1-adrenoceptor oligomerization. Here, assessment of the dissociation rate of a fluorescent analog of CGP 12177 [bordifluoropyrromethane-tetramethylrhodamine-(±)CGP 12177 (BODIPY-TMR-CGP)] at the human β1-adrenoceptor expressed in Chinese hamster ovary cells revealed negative cooperative interactions between 2 distinct β1-adrenoceptor conformations. The dissociation rate of 3 nM BODIPY-TMR-CGP was 0.09 ± 0.01 min(-1) in the absence of competitor ligands, and this was enhanced 2.2- and 2.1-fold in the presence of 1 µM CGP 12177 and 1 µM propranolol, respectively. These effects on the BODIPY-TMR-CGP dissociation rate were markedly enhanced in β1-adrenoceptor homodimers constrained by bimolecular fluorescence complementation (9.8- and 9.9-fold for 1 µM CGP 12177 and 1 µM propranolol, respectively) and abolished in β1-adrenoceptors containing TM4 mutations vital for the second conformation pharmacology. This study suggests that negative cooperativity across a β1-adrenoceptor homodimer may be responsible for generating the low-affinity pharmacology of the secondary β1-adrenoceptor conformation.
在β1 - 肾上腺素能受体上,CGP 12177在主要的高亲和力儿茶酚胺构象下能有效拮抗激动剂反应,同时还能通过次要的低亲和力构象发挥自身的激动剂作用。最近的一项诱变研究确定β1 - 肾上腺素能受体的跨膜区(TM)4是这种低亲和力构象的关键。其他人则认为TM4在β1 - 肾上腺素能受体寡聚化中起作用。在此,对在中国仓鼠卵巢细胞中表达的人β1 - 肾上腺素能受体上CGP 12177的荧光类似物[硼二氟吡咯甲烷 - 四甲基罗丹明 - (±)CGP 12177(BODIPY - TMR - CGP)]的解离速率进行评估,结果显示在两种不同的β1 - 肾上腺素能受体构象之间存在负协同相互作用。在没有竞争配体的情况下,3 nM BODIPY - TMR - CGP的解离速率为0.09±0.01 min⁻¹,而在存在1 μM CGP 12177和1 μM普萘洛尔时,分别提高了2.2倍和2.1倍。这些对BODIPY - TMR - CGP解离速率的影响在受双分子荧光互补限制的β1 - 肾上腺素能受体同二聚体中显著增强(对于1 μM CGP 12177和1 μM普萘洛尔分别为9.8倍和9.9倍),而在含有对第二种构象药理学至关重要的TM4突变的β1 - 肾上腺素能受体中则被消除。这项研究表明,β1 - 肾上腺素能受体同二聚体之间的负协同作用可能是产生次要β1 - 肾上腺素能受体构象低亲和力药理学的原因。